Page 66 - 2017 V1 InsideOut

NewProducts Available from ASD Healthcare
Ne
ASD Healthcare is now an authorized distributor for several new products, which are described here. We continuously expand our product lines to make sure you have access to the products you need, when you need them. To verify a product is appropriate to order for your facility, simply call your sales representative.
We’re always here to help you.
Azacitidine for Injection
Manufactured by Wockhardt, USA LLC, azaciti- dine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syn- drome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in trans- formation (RAEB-T), and chronic myelomono- cytic leukemia (CMMoL).
For specific product ordering information, please see page 74 in our Product Catalog.
Bavencio®
Manufactured by EMD Serono, Bavencio (ave- lumab) is indicated for the treatment of adults and pediatric patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. Baven- cio received orphan drug status and is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.
For specific product ordering information, please see page 74 in our Product Catalog.
Benlysta®
Manufactured by GlaxoSmithKline, Benlysta (belimumab) is indicated for treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiv- ing standard therapy.
For specific product ordering information, please see page 79 in our Product Catalog.
LENVIMA®
Manufactured by Eisai, LENVIMA (lenvatinib) is indicated for treatment of differentiated thyroid cancer that can no longer be treated with radioactive iodine and is progressing. LENVIMA is also indicated for use, along with everolimus, to treat advanced RCC, a type of kidney cancer, after one course of treatment with another anti-cancer medicine.
For specific product ordering information, please see page 75 in our Product Catalog.
OCREVUSTM
Manufactured by Genentech, OCREVUS (ocrelizumab) is indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. OCREVUS is the
first and only medicine to receive FDA approval for both relapsing and primary progressive forms of multiple sclerosis.
For specific product ordering information, please see page 80 in our Product Catalog.
SalivaMAXTM
Manufactured by Forward Science, LLC, SalivaMAX is a supersaturated calcium phos- phate powder that, when dissolved in water, creates a solution with a high concentration
of electrolytes similar to that of natural saliva. SalivaMAX is an artificial saliva that is used
to relieve acute and chronic symptoms of xerostomia (dry mouth). Supersaturated calcium phosphate rinses have been clinically proven to reduce the symptoms of xerostomia (dry mouth) due to medications, dysfunction of the salivary glands, Sjögren’s syndrome, chemotherapy and radiation treatment.
For specific product ordering information, please see page 81 in our Product Catalog.
Treanda®
Manufactured by Teva Pharmaceuticals, Treanda (bendamustine HCl) is indicated for the treatment of patients with chronic lympho- cytic leukemia (CLL) or B-Cell non-Hodgkin lymphoma (NHL).
For specific product ordering information, please see page 76 in our Product Catalog.
Vonvendi®
Manufactured by Shire PLC, Vonvendi [von Willebrand factor (recombinant)] is the first
and only recombinant von Willebrand Factor. Vonvendi is indicated for on-demand treat- ment and control of bleeding episodes in adults diagnosed with von Willebrand disease.
For specific product ordering information, please see page 70 in our Product Catalog.
ZejulaTM
Manufactured by Tesaro, Inc., Zejula (niraparib) is a capsule indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or par- tial response to platinum-based chemotherapy. Zejula received orphan drug designation specifically for its use in treating recurrent epithelial ovarian cancer.
For specific product ordering information, please see page 77 in our Product Catalog.
62 | InsideOut
w